About Envisagenics
Envisagenics is a company based in Long Island City (United States) founded in 2014 by Martin Akerman and Maria Luisa Pineda. Envisagenics has raised $46.78 million across 9 funding rounds from investors including New York State, HHS and Bristol-Myers Squibb. Envisagenics offers products and services including SpliceCore and SpliceIO. Envisagenics operates in a competitive market with competitors including Genomics, Seven Bridges Genomics, Dicerna Pharmaceuticals, Depixus and Ingenuity Systems, among others.
- Headquarter Long Island City, United States
- Founders Martin Akerman, Maria Luisa Pineda
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$46.78 M (USD)
in 9 rounds
-
Latest Funding Round
$25 M (USD), Series B
Jun 05, 2024
-
Investors
New York State
& 15 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Envisagenics
Envisagenics offers a comprehensive portfolio of products and services, including SpliceCore and SpliceIO.
AI tool for discovering RNA splicing drug targets
Identifies tumor-specific neoepitopes for therapies
People of Envisagenics
Unlock access to complete
Unlock access to complete
Funding Insights of Envisagenics
Envisagenics has successfully raised a total of $46.78M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $25 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Envisagenics
Envisagenics has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include New York State, HHS and Bristol-Myers Squibb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Technology companies are incubated by Red Cell Partners for critical sectors.
|
Locked | Locked | Locked | |
|
Venture capital investments in technology startups are facilitated by M12.
|
Locked | Locked | Locked | |
|
Venture capital investing in AI, biotech, and technology sectors, focusing on seed and early stages in Seattle and beyond.
|
Locked | Locked | Locked |
Investor details for Envisagenics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Envisagenics
Investment portfolio details for Envisagenics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Envisagenics
Detailed financials for Envisagenics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Envisagenics Comparisons
Peer comparison for Envisagenics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Envisagenics
Envisagenics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Genomics, Seven Bridges Genomics, Dicerna Pharmaceuticals, Depixus and Ingenuity Systems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomic risk assessment and prevention platform is provided.
|
|
| Locked | Locked | Locked |
Cloud-based platform to analyze, store, and act on genomic data.
|
|
| Locked | Locked | Locked |
Drugs are developed using RNA interference technology platform.
|
|
| Locked | Locked | Locked |
Single-molecule genetic and epigenetic sequencing solutions are provided.
|
|
| Locked | Locked | Locked |
Genomic data is analyzed and interpreted via web-based applications.
|
|
| Locked | Locked | Locked |
RNAi therapeutics are developed for dermal, ophthalmic, and pulmonary diseases.
|
Detailed competitors of Envisagenics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Envisagenics
Complete news archive for Envisagenics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Envisagenics
Envisagenics was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Envisagenics is headquartered in Long Island City, United States. It is registered at Long Island City, New York, United States.
Maria Luisa Pineda is the current CEO of Envisagenics. They have also founded this company.
Envisagenics is a funded company, having raised a total of $46.78M across 9 funding rounds to date.
Envisagenics was founded in 2014 and is based in Long Island City, United States. Operations center on the biotechnology sector, where novel RNA splicing therapeutics are discovered and developed using artificial intelligence. A cloud-based platform called SpliceCore is provided, which has been experimentally validated to predict drug targets and biomarkers via splicing analysis of RNA-seq data.
Envisagenics's top competitors include Dicerna Pharmaceuticals, Eagle Genomics and Orna.
Envisagenics offers SpliceCore and SpliceIO.
Envisagenics has 16 investors. Key investors include New York State, HHS, Bristol-Myers Squibb, National Cancer Institute, and Red Cell Partners.